



Citation for published version:

Bates, G & Vinther, AS 2021, 'Applying insights from implementation and intervention science to improve the evidence base on image and performance-enhancing drugs (IPEDs) interventions', *Performance Enhancement and Health*, vol. 9, no. 2, 100193. <https://doi.org/10.1016/j.peh.2021.100193>

DOI:

[10.1016/j.peh.2021.100193](https://doi.org/10.1016/j.peh.2021.100193)

Publication date:

2021

Document Version

Peer reviewed version

[Link to publication](#)

Publisher Rights

CC BY-NC-ND

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Applying insights from implementation and intervention science to improve the evidence base on image and performance-enhancing drugs (IPEDs) interventions

[Accepted version; May 2021]

Authors and affiliations:

Geoff Bates¹ (corresponding author), Anders Schmidt Vinther²

¹Institute for Policy Research, University of Bath, Claverton Down Campus, Bath, BA2 7AY; e-mail: gb818@bath.ac.uk (Twitter: @bates_g)

²Department of Public Health, Aarhus University, Bartholins Alle 2, Building 1260, DK-8000 Aarhus; email: asv@ph.au.dk (Twitter: @ASVinther)

Declaration of interest

ASV has received financial support from Anti Doping Denmark.

GB is currently the recipient of funding from the National Institute of Health Research in the UK, to undertake research around IPED interventions.

Abstract:

Recent decades have seen increased public attention devoted to the use of image and performance-enhancing drugs (IPEDs). As research into the epidemiology and aetiology of IPED use has grown substantially, so has interest amongst scholars and policy makers in developing and implementing a variety of public health interventions that target potential and current IPED users. However, the evidence base on IPED interventions remains underdeveloped and few firm conclusions can be made about their impact. In short, we know very little about whether IPED interventions are appropriate, effective, ineffective, or even harmful, or why and how this is the case. In this article, we make the case for applying recent insights from intervention and implementation science to better assess the problems that require intervention, enhance the development, implementation and evaluation of IPED interventions, and improve the quality and size of the evidence base. This is necessary if we are to develop evidence-based IPED interventions that support good health and avoid the potential to do harm. We begin by discussing the different types of IPED interventions that have been introduced and what we know about their impact from the limited evaluations that have been published to date. We then discuss how methods and frameworks from intervention and implementation science can provide important insights that will greatly enhance the development, implementation, and evaluation of these interventions. Drawing on examples of IPED interventions implemented in a variety of countries we explore how these methods can be applied by those working in this field and identify guidance and tools that support their uptake. We conclude by proposing five key priorities to support the development of a more robust evidence base of IPED interventions that will, ultimately, support an evidence-based public health response to IPED use.

Keywords: IPEDs, interventions, public health, implementation science

1 **1. Introduction**

2 In the three decades since the need for interventions to address the use of image and performance-
3 enhancing drugs (IPEDs) was first discussed (Council on Scientific Affairs, 1988; Marcello et al., 1989;
4 Morrison, 1994; Nutter, 1993), a wide range of interventions have been introduced (Backhouse et al.,
5 2016; Bates, Begley, et al., 2019; Bates, Van Hout, et al., 2019; Christiansen et al., 2019; Johannisson
6 et al., 2012). Whilst these interventions represent a variety of guiding principles, goals, approaches,
7 populations, and settings, they share a common ambition to prevent and reduce IPED-related health
8 risks in order to improve public health. IPEDs, the most commonly studied of which are anabolic
9 androgenic steroids (AAS), are associated with increasing risk of experiencing a range of side effects
10 and harmful physical and psychological health outcomes that range from cosmetic to acute and
11 chronic. These have been extensively summarised elsewhere (ACMD, 2010; McVeigh & Begley, 2017;
12 Pope et al., 2014) but include concerns such as changes to cognitive function (Bjørnebekk et al., 2019),
13 cardiovascular disease (Baggish et al., 2017; Rasmussen et al., 2018; Thiblin et al., 2015), reproductive
14 dysfunction (Christou et al., 2017), blood-borne virus transmission (Hope et al., 2016), injection site
15 injuries and infections (Hope et al., 2015), and dependence (Kanayama et al., 2009).

16 Our understanding of the associations between IPED use and harm is still developing, but factors such
17 as dosage, length of time that IPEDs are used for, and mode of administration appear important (Pope
18 et al., 2014). People who use IPEDs represent a heterogeneous population with variation in their usage
19 pattern, their motivations, and their level of risk (Christiansen et al., 2017; Zahnow et al., 2018). Their
20 decisions and experience of harms are therefore likely to vary, suggesting that no 'one size fits all'
21 approach is likely to be suitable. Instead, a variety of interventions will be required as part of an
22 effective public health response.

23 However, it is unclear whether these interventions are in fact effective or not at achieving their aims,
24 or if they are even potentially causing harm. For instance, there is some evidence from evaluations of
25 IPED prevention interventions to suggest that these interventions may actually harm the target

26 population (Elbe & Brand, 2016; Goldberg et al., 2003; Goldberg et al., 2007; Sagoe et al., 2016), yet
 27 many interventions currently being delivered have not been rigorously evaluated to address their
 28 impact. Additionally, it is unclear whether IPED interventions are being developed according to a
 29 thorough assessment of the problem and therefore whether the approaches taken are optimal,
 30 necessary, or ethically justifiable; particularly when we do not know what their impact is. Table 1
 31 presents a brief overview of different types of IPED interventions, including their characteristics and
 32 an assessment of the strength of the current evidence base to support their impact based upon the
 33 number and methodological quality of available evaluation studies. Its purpose is to demonstrate the
 34 variety of IPED interventions that have been developed and the state of the evidence base evaluating
 35 these interventions.

36 Table 1. Types of IPED interventions and the content and quality of the available evidence base
 37 evaluating these interventions.

Intervention category	Primary aim	Primary target population	Example approaches (example studies)	Strength of the evidence base
Universal prevention/ health promotion	To prevent initiation of IPED use	Low risk non-users	School-based education of adolescents (Elliot et al., 2004; Goldberg, Elliot, Clarke, MacKinnon, Zoref, et al., 1996)	Fair: Includes several evaluations of mixed methodological quality
Targeted prevention	To prevent initiation of IPED use	High-risk non-users	Anti-doping campaigns or education in gyms (Jalilian et al., 2011; Molerio et al., 2016)	Weak: Includes few evaluations of mixed methodological quality
Harm reduction	To promote safe initiation of IPED use and prevent/reduce health risks from IPED use	IPED users	Provision of injecting equipment; advice and information (NICE, 2014)	Weak to non-existent: Includes very few evaluations
Treatment/ recovery	To promote and support cessation and abstinence/ treat related medical conditions	IPED users and ex-users	Treatment of IPED dependence; motivating cessation (Oslo University Hospital, 2020; Region Örebro County, 2020; Smit & de Ronde, 2018)	Weak to non-existent: Includes very few evaluations

38

39 The table and accompanying discussion of the extent and limitations of the evidence base are based
40 on the findings of recent systematic reviews that have identified and assessed the available evidence
41 from evaluations of prevention, harm reduction and treatment interventions related to IPED use
42 (Backhouse et al., 2016; Bates, Begley, et al., 2019; Bates et al., 2014; Bates, Van Hout, et al., 2019).
43 In addition to this, we cite examples of IPED interventions identified through our work in the field that
44 have been developed but that have not been subject to formal evaluation, or at least for which no
45 evaluation has been published internationally. These examples are not intended to be an exhaustive
46 list, as we recognise there may be numerous other examples of interventions of all types that have
47 not been subject to any evaluation.

48 The table highlights that many different types of IPED interventions have been developed and
49 delivered to different populations of people who use (or are at risk of using) IPEDs and with different
50 goals, but that published evaluations of most of these approaches are rare or even non-existent. We
51 believe that breaking down these interventions by target population or goal (e.g., to prevent initiation
52 of IPED use or to reduce harm amongst people who already use IPEDs) is a helpful way to make sense
53 of and identify gaps in the evidence base, and to recognise that interventions have been developed to
54 respond to different problems. Different approaches have been favoured in different countries (for
55 example, a harm reduction approach in the UK compared with a primary prevention/treatment
56 approach in Scandinavia) and with different populations (for example, education for young athletes
57 compared with provision of health services for adults who choose to use IPEDs), and referring to IPED
58 interventions as one group is potentially confusing and misleading.

59 We believe that enhancing the size and quality of the IPED intervention evidence base is long overdue.
60 In this article we discuss the gaps in the evidence and their implications, before highlighting how we
61 can better develop evidence-based IPED interventions. We introduce methods and principles from the
62 fields of intervention and implementation science that together help public health researchers and
63 practitioners to assess the problems they wish to address, and to systematically develop, implement

64 and evaluate interventions based upon this assessment. We conclude by identifying five key priorities
65 to improve the IPED intervention evidence base that we believe are necessary if we are to produce
66 effective, appropriate and sustainable public health IPED interventions.

67 **2. The state of the evidence on IPED interventions**

68 The IPED intervention literature is dominated by academic-led evaluations of universal prevention
69 programs that have typically been delivered in schools to adolescents in the US and Europe
70 (Backhouse et al., 2016; Bates, Begley, et al., 2019; Christiansen, 2020). Many appear based on limited
71 theoretical foundations, and little is known about whether they are effective or not at preventing
72 subsequent IPED use, as their impact has only been evaluated in the short-term (Bates, Begley, et al.,
73 2019). While this literature therefore represents, at best, an incomplete evidence base, it is far more
74 advanced in comparison to the evidence on the other categories of IPED interventions presented in
75 table 1. There is a significant gap therefore between the number of interventions being delivered
76 internationally to address IPED use and the number of studies available in the academic literature
77 describing and evaluating such interventions.

78 The response to IPED use has varied internationally in the focus and type of interventions. For
79 example, in countries such as the UK and Australia, needle and syringe programmes (NSPs) have long
80 provided health and harm reduction interventions to IPED users, primarily through the provision of
81 sterile injecting equipment. In the UK, specialist IPED clinics have been championed since the 1990s
82 as settings to engage with users and deliver harm reduction interventions (Kimergard & McVeigh,
83 2014; Morrison, 1994). Community-based prevention approaches based broadly on ‘anti-doping’
84 principles but applied to recreational IPED users have been introduced in Scandinavia, Austria, the
85 Netherlands, and Belgium, for example through law enforcement and drug testing approaches in gyms
86 alongside a range of other preventive measures such as certification schemes and education
87 campaigns (Christiansen, 2020; Christiansen et al., 2019; Johannisson et al., 2012; van de Ven, 2016).
88 Apart from a few examples, however, it is unclear to what extent these approaches have been

89 systematically developed and whether any of these interventions are effective or perhaps even
90 harmful as we do not have examples of published evaluations to draw upon (Backhouse et al., 2016;
91 Bates, Begley, et al., 2019; Bates et al., 2014; Bates, Van Hout, et al., 2019). If we consider that it is
92 almost exclusively interventions that fall within the area of universal prevention that have been
93 subject to robust evaluation, the evidence base on IPED interventions has clearly not kept up with the
94 ever-increasing body of evidence exploring the prevalence and correlates of IPED use (Blank et al.,
95 2016; Brennan et al., 2017; Ntoumanis et al., 2014; Sagoe, Molde, et al., 2014), the motivations and
96 behaviours of IPED users (Sagoe, Andreassen, et al., 2014), and the associated physiological and
97 psychological harms (ACMD, 2010; Christou et al., 2017; Kanayama et al., 2009; Pope et al., 2014).

98 There is a clear need therefore for evidence of the impact of existing interventions and evaluations of
99 factors influencing their implementation. The challenge for those working with IPED interventions is
100 to i) identify the best evidence available to support the development, implementation, and delivery
101 of effective interventions; and ii) to improve the evidence base by prioritising evaluation of these
102 interventions. Importantly, these should not be understood as distinct processes, but rather as part
103 of an ongoing process of developing a deeper understanding of what works for different populations
104 and in different contexts. A mature evidence base will not only include studies that evaluate
105 intervention effectiveness but also enable us to understand how these different interventions work
106 and what factors will lead to variation in delivery and impact.

107 **3. A science of interventions**

108 One key step towards developing a high-quality evidence base of IPED interventions is to apply
109 principles and practice from the growing field of intervention and implementation science. In the
110 context of public health, implementation science can be defined as the study of methods to promote
111 the uptake of research and evidence into practice (Eccles & Mittman, 2006). It emphasizes the design
112 and evaluation of interventions, including how and under what circumstances the intervention brings
113 about change. Substantial advances have been made within this field in the past two decades in terms

114 of developing methods, frameworks, models, and approaches to design, evaluate, implement, and
115 adapt so-called 'complex interventions' that together support the adoption of a scientific approach to
116 interventions (Craig et al., 2008; Minary et al., 2019; Movsisyan et al., 2019; Nilsen, 2015; O'Cathain
117 et al., 2019; Richards & Hallberg, 2015). The term 'complex intervention' is used within public health
118 research to describe interventions delivered in a natural or 'real world' context that aim to prevent,
119 promote, change, or maintain health-related behaviour to improve public health. The multifaceted
120 nature of the issues that complex interventions seek to address (i.e., various influences across
121 different 'socioecological levels') means that they do not lend themselves to the same level of control
122 as, for instance, pharmacological or exercise interventions that are often conducted under tightly
123 controlled laboratory conditions. Since many IPED interventions share these characteristics, we
124 believe this research area is a good starting point for advancing IPED intervention research.

125 Applying concepts from implementation science can help improve our understanding of IPED
126 interventions. Given that relevant 'justificatory conditions' such as *necessity* and *proportionality* are
127 met (Childress et al., 2002), one of the most important questions to address when evaluating a public
128 health intervention undoubtedly is if it works. Two closely related questions concern *how well* it works
129 and whether it is *cost-effective*. Indeed, outcome and economic evaluations that examine the
130 direction, magnitude, and persistence of potential intervention effects, as well as the costs weighed
131 against the benefits are important because they provide policy makers, intervention developers, and
132 other relevant stakeholders with crucial information to support them in deciding whether to adopt an
133 intervention and implement it into routine practice (Craig et al., 2008; Minary et al., 2019). However,
134 important as they are, these questions do not tell the full story. For instance, the fact that most school
135 based IPED interventions have little or no impact on behavioural outcomes does not necessarily mean
136 that these interventions are ineffective and should be discarded accordingly (Bates, Begley, et al.,
137 2019). Rather, this begs the question: *Why didn't they work?*

138 Interventions may be ineffective for several reasons, including when they are based on an inadequate
139 understanding of the problem (a weak ‘theory of the problem’) or when the intervention content is
140 inappropriate to bring about the desired change (a weak ‘theory of change’) (Bartholomew et al.,
141 2006). However, the lack of impact may also be explained by issues that do not relate to the
142 intervention content *per se*, but instead to how the intervention was implemented and delivered.
143 Examples of factors that may have undermined intervention effectiveness are low implementation
144 fidelity (i.e., the intervention was not delivered as intended), timing and dosage of the intervention,
145 and a failure account for contextual factors affecting intervention outcomes. Exploring these issues in
146 a process evaluation provides a unique opportunity to learn what might (or might not) work for whom
147 under what circumstances. Process evaluation can also be used to investigate ‘causal pathways’ or
148 ‘mechanisms of actions’, that is, the processes through which an intervention brings about change
149 (Craig et al., 2008; Moore et al., 2014).

150 There is a third possibility that relates to the selection of intervention outcomes. Critics could
151 reasonably object that the school based IPED interventions mentioned above are weighed on the
152 wrong scale: Given the low baseline levels of IPED use consistently observed across these
153 interventions, it is unfair to determine their impact based on whether they are successful in reducing
154 the prevalence of IPED use. Since few IPED users (approximately 20% for AAS) initiate their use of
155 these drugs before age 20, and almost none before age 16 (Pope et al., 2014), the often limited
156 timeframe of these interventions (short duration and lack of long-term follow-up) makes it difficult to
157 detect reductions in actual IPED use (Bates, Begley, et al., 2019). While we agree with this critique, it
158 stands in contrast with the explicit aim of these interventions to ‘prevent’ or ‘reduce’ actual IPED use
159 (Bates, Begley, et al., 2019). This points to the importance of carefully aligning the aims and outcomes
160 of an intervention with the nature and characteristics of the problem that it seeks to address. Instead,
161 these interventions should be deemed successful if they cost-effectively reduce risk factors for IPED
162 use (or increase protective factors). For instance, the ATLAS intervention, which aimed to prevent AAS
163 use amongst adolescent (student) athletes, had positive and lasting effects on important risk factors

164 for AAS use such as intentions to use AAS, AAS knowledge and attitudes, and skills to resist drug offers
165 (Goldberg, Elliot, Clarke, MacKinnon, Moe, et al., 1996).

166 **4. Applying insights from intervention and implementation science to IPED interventions**

167 ***4.1 Developing and implementing interventions***

168 In their highly influential 2008 article that has been cited over 8,000 times and applied to a wide range
169 of health topics and settings, the UK Medical Research Council published guidance on the
170 development and evaluation of complex interventions that emphasised the importance of
171 development and piloting work during early stages (Craig et al., 2008). In line with this, a number of
172 recent intervention development approaches highlight the need to spend considerable amounts of
173 time during this stage in order to fully understand the problem and its causes, and identify a feasible
174 intervention strategy, before proceeding to large-scale evaluation (Campbell et al., 2007; Fraser et al.,
175 2009; Gitlin & Czaja, 2015; Hawkins et al., 2017; Michie et al., 2014; Wight et al., 2016). Interventions
176 that are not carefully developed or based on a thorough understanding of the problem are less likely
177 to be effective and more likely to cause harm. It is well established that interventions may, despite
178 good intentions, negatively impact the target population. This can undermine the net benefit of an
179 intervention and the risk of harmful effects should therefore be kept in mind throughout the entire
180 intervention development and evaluation process (Bonell et al., 2015; Michie et al., 2014). We
181 recognise that not all teams working on IPED interventions will want to, or have the resources to,
182 engage fully with these highly systematic and technical approaches, but may still apply the principles
183 and concepts they promote.

184 The development of intervention strategies supported by guidance and focussing on implementation
185 and design factors has been readily adopted by teams developing health interventions in other fields,
186 for example in smoking cessation interventions (Fulton et al., 2016; Gould et al., 2017; Tombor et al.,
187 2016), which has helped to advance the evidence base considerably. Adopting a similar approach to
188 developing IPED interventions would have great benefits to this field. Fundamentally, a better

189 understanding of the problem will support the design of more effective interventions based upon
190 appropriate strategies rather than assumptions of what might work. This is a well-recognised problem
191 in interventions seeking to change health behaviours, which are commonly based on pre-determined
192 assumptions rather than a thorough analysis of the problem and what actually needs to change
193 (Brown et al., 2020; Michie et al., 2014). Involving stakeholders in development can improve the
194 understanding of what needs to change, as well as the factors likely to affect implementation
195 (O’Cathain et al., 2019). For example, those aiming to address IPED use within gyms can consider
196 engaging during development with people who use IPEDs as well as gym staff and local health
197 professionals to understand what is needed, and what is feasible to be implemented. This engagement
198 can be an ongoing process, and intervention providers can seek feedback and assess the extent to
199 which the intervention is effective. Where this is already happening, making the findings of such
200 engagements available so that other researchers and practitioners can learn from them will help to
201 improve the evidence base.

202 Beyond failing to improve public health, interventions that are revealed to be ineffective or
203 unsustainable are a waste of the scarce resources and limited opportunity to intervene that those
204 working in this field will no doubt be familiar with. Therefore, it is critical to consider implementation
205 during intervention development. Various principles and recommendations for decision-making
206 during intervention development have been proposed. An example is the APEASE criteria which can
207 be employed to assess intervention affordability, practicability, effectiveness and cost-effectiveness,
208 acceptability, side-effects, and equity (Michie et al., 2014). Similarly, in their study identifying
209 interventions to prioritise relating to physical activity interventions, Morton and colleagues (2017)
210 propose to consider factors including intervention reach, equality, acceptability and cost, as well as
211 effectiveness. While this may seem like a daunting task, by developing a thorough understanding of
212 the problem and its context, our understanding of these implementation issues will improve.

213 With few exceptions, authors of IPED intervention evaluations provide little detail about how and why
214 interventions were developed (Bates, Begley, et al., 2019; Bates, Van Hout, et al., 2019). Studies such
215 as evaluations of the ATLAS study (Goldberg, Elliot, Clarke, MacKinnon, Zoref, et al., 1996; MacKinnon
216 et al., 2001) demonstrate how theory can be used to support intervention development, but generally
217 the IPED intervention literature contains scant detail on the theory underpinning interventions or the
218 process of development. This question of why interventions have been developed in the manner they
219 have might lead us to question the justification for well-established approaches. For example, the
220 provision of sterile injecting equipment to reduce transmission of blood-borne viruses (BBVs) has long
221 been the focus of the UK government's IPEDs policy (HM Government, 2017; Independent Expert
222 Working Group, 2017). However, it is unclear on what basis needle and syringe programmes in
223 pharmacies and drug treatment services have been determined to be the most suitable setting to
224 deliver this intervention to UK IPED users, or why BBV prevention is prioritised over other types of
225 interventions that UK stakeholders have identified as being as, if not more, important (Bates et al.,
226 2021). Likewise, there is currently no evidence to support the deterrent and preventive effects of drug
227 testing in gyms, yet drug testing has remained a core element of the anti-doping campaign in Danish
228 gyms for almost two decades. Adding to this uncertainty is the fact that others have questioned the
229 proportionality of this approach because the (potential) public health benefits of testing does not
230 seem to outweigh the infringement of gym users' rights to privacy and bodily integrity (Christiansen,
231 2020).

232 **4.2 Reporting studies**

233 Transparency is critical to support knowledge transfer and the replication of interventions, and to
234 understand why they were effective or not. However, in many of the studies of IPED interventions, it
235 is challenging for the reader to understand what the specific components are in the intervention
236 (Bates, Begley, et al., 2019). It is important that authors provide sufficient information for others to
237 understand specifically what was delivered, and how. The TIDieR checklist (Hoffmann et al., 2014) has

238 been designed to help authors describe their interventions in sufficient detail for interventions to be
239 replicated by other research teams and has been widely adopted. Reporting standards have been
240 adopted by researchers to improve transparency and quality of reporting in studies based on a variety
241 of designs, such as CONSORT (Schulz et al., 2010) for randomised controlled trials and TREND (Des
242 Jarlais et al., 2004) for nonrandomised evaluations of behavioural and public health interventions.
243 Journal editors can support this improved quality and transparency in reporting by encouraging or
244 even requiring authors to refer to these standards.

245 ***4.3 Assessing feasibility***

246 Conducting a small-scale pilot study during the final stages of intervention development is a useful
247 way to explore the feasibility of an intervention before it is tested and evaluated in a large-scale trial.
248 Results from a pilot study can give early indications of intervention (in)effectiveness or potential harms
249 caused by the intervention and provide key insights into factors that may impede or enhance
250 implementation quality such as acceptability amongst decision makers, intervention providers, and
251 the target population (Craig et al., 2008). In the context of IPED interventions, pilot work is rarely
252 reported in evaluation studies (Bates, Begley, et al., 2019). Thus, it appears that IPED interventions
253 are generally designed without a preliminary assessment of feasibility. Although piloting of an
254 intervention prior to evaluation is no guarantee of success, we contend that it is beneficial to do so.
255 To illustrate, Elbe & Brand (2016) evaluated the effects of an ethical decision-making training program
256 to prevent the use of IPEDs amongst young athletes. Contrary to the authors' expectations, it turned
257 out that athletes in the intervention group had more positive attitudes toward performance
258 enhancing drugs at post-intervention when compared with standard anti-doping education and no
259 education (Elbe & Brand, 2016). The unintended intervention effects observed in this intervention
260 (i.e., more positive drug attitudes) could have been addressed, and perhaps even prevented, had a
261 small-scale pilot study been conducted during intervention development.

262 ***4.4 Evaluating interventions***

263 To improve the current evidence base there is a need firstly to start evaluating the public health
264 interventions already in place internationally, such as IPED interventions being delivered by local
265 authorities, public health agencies, and anti-doping organisations. Secondly, and of equal importance,
266 the results from these evaluations need to be disseminated internationally in reports or scientific
267 journals to support the sharing of good practice. As mentioned earlier, national anti-doping campaigns
268 in gyms have long served as the main public health response to IPED use in many European countries
269 (Christiansen et al., 2019; Johannisson et al., 2012). However, despite their shared aim of ultimately
270 preventing IPED use, very little is known about the impact of these interventions on *actual IPED use*.
271 This is not to say that for these interventions there are no evaluations available of any kind, but rather
272 that when evaluations are conducted, they rarely measure the impact of the intervention on long-
273 term behavioural outcomes. In addition, when evaluations are performed, the results of these
274 evaluations are rarely disseminated to a wider audience. One exception is the Swedish programme,
275 100% Pure Hard Training, a community-based intervention that has been delivered in Swedish gyms
276 since 2007 (Molero et al., 2016). This programme has been formally evaluated twice (in 2010 and
277 2018) using a quasi-experimental design and showed promising, albeit statistically uncertain, effects
278 (Christiansen et al., 2019; Dehnov & Molero, 2018; Johannisson et al., 2012).

279 There may be several explanations for the shortcoming of internationally available, robust evaluations
280 of IPED interventions. Whilst we can only speculate about the reasons why local and national
281 stakeholders rarely evaluate the impact of their IPED interventions, a recent pan-European study of
282 IPED prevention in recreational sport identified a number of 'implementation barriers' that may also
283 apply to evaluation more generally. When asked to list the most important barriers to implementing
284 prevention in recreational sport, European stakeholders reported 'lack of financial and human
285 resources' to be the most important barrier followed by 'lack of cooperation between key
286 stakeholders' and 'lack of good practice' (Christiansen et al., 2019). Since it requires expertise and can
287 be time consuming to set up, conduct, and report the results of evaluations, other tasks such as the
288 day-to-day coordination and delivery of the intervention might take priority over evaluation for

289 stakeholders providing the types of interventions discussed in this article. It may also be that
290 evaluations are taking place, but that findings are not being promoted widely or published in
291 accessible places.

292 Another possible explanation for the lack of evaluations relates to the discrepancy between
293 researchers' and practitioners' preferences and needs in terms of selecting an appropriate study
294 design. There has long been a tendency amongst scholars and policy makers alike to favour the
295 randomised controlled trial (RCT) as the golden standard of evidence when it comes to evaluating
296 public health interventions, even when the classical RCT is not necessarily the most appropriate design
297 (Craig et al., 2008; Victora et al., 2004). There are many reasons for the widespread preference of the
298 RCT design including the scientific obsession with internal validity, that is, the ability to establish a
299 cause-and-effect relationship and rule out alternative explanations, at the cost of external validity,
300 that is, the generalizability of findings beyond the 'laboratory setting' (Minary et al., 2019). This may
301 in part explain the fact that most published IPED interventions are educational interventions aimed at
302 preventing IPED use in school populations. Because the school setting lends itself more easily to high
303 levels of control than, say, an entire community, school-based interventions sit well with the RCT
304 design. Indeed, few (if any) designs outperform the RCT in terms of drawing causal inferences about
305 intervention effects under controlled conditions (Victora et al., 2004).

306 However, regardless of the short-term impact they may have on behaviour, it is unlikely that
307 standalone interventions delivered in schools will lead to sustained behaviour change due to the host
308 of risk factors that many individuals will inevitably be exposed to beyond the school setting. Thus,
309 although school interventions may theoretically prevent future IPED use initiation through a reduction
310 of risk factors (or an increase in protective factors), these effects are unlikely to persist unless they are
311 reinforced in other interventions such as targeted interventions in high-risk environments like gyms
312 or sports clubs. The predominant focus in academia on evaluating standalone IPED interventions in
313 RCTs despite the need for evaluations of system-wide interventions has led to increased scepticism

314 and reluctance amongst some stakeholders to engage with the academic community and, as a result,
315 missed opportunities to assess the impact of IPED interventions that are already in place. As pointed
316 out by a representative of the UK national anti-doping organisation (UKAD) in a recent study of doping
317 prevention in recreational sport across the EU28:

318 *“As outsiders, we see the academic community spending money and resources towards the benefit of*
319 *clean sport. We support this absolutely. However, some challenges exist for us. Typically, the research*
320 *proposal is centred on a one-off intervention which we know do not work [...] That information*
321 *[obtained from single interventions] is part of a larger system, which we are trying to embed in the*
322 *environment. And it is that system we want to evaluate, not the one-off intervention.”* (Christiansen et
323 al., 2019, p. 60)

324 The idea that interventions such as those alluded to above should be regarded, not as single events to
325 be evaluated in isolation, but rather as parts of a wider prevention system consisting of multiple but
326 complementary interventions aligns with a recent shift in public health research towards considering
327 interventions as ‘events’ in complex systems (Hawe et al., 2009; Moore et al., 2019). It is often
328 necessary to employ more flexible and pragmatic designs (e.g., pragmatic RCTs, realist evaluation, or
329 natural experiments) when evaluating these types of interventions because the causal chain between
330 the intervention components and the outcomes are often long and complex (Minary et al., 2019;
331 Victora et al., 2004). A ‘systems approach’ to interventions may provide a useful conceptual
332 framework for future work on IPED interventions because it seems to strike the right balance between
333 the scientific interest in isolating causal mechanisms and a more pragmatic interest in what works in
334 ‘the real world’. Taking such an approach may help to reduce the research/practice-gap described
335 above and, ultimately, overcome key barriers that are currently preventing IPED interventions from
336 being evaluated. However, it is beyond the scope of this article to explore in detail what a systems
337 approach to IPED use might look like.

338 **5. Conclusion**

339 In the past thirty years researchers and practitioners have developed and delivered a wide range of
340 interesting and innovative interventions to address IPED use. In this article, we have made the case
341 for embracing the principles of implementation and intervention science in the IPED intervention field
342 to i) enhance the quantity and quality of this evidence base, and ii) support the development of
343 interventions that are appropriate, justifiable, feasible, sustainable and effective in line with their
344 goals and the needs of the populations they target. This is necessary now if we are to develop
345 evidence-based public health interventions that respond to IPED use, support population health and
346 avoid causing harm. Based on our analysis in this article and our reflections on the evidence presented
347 in recent systematic reviews (Bates et al., 2014; Bates, Begley et al., 2019, Bates, Van Hout et al., 2019;
348 Backhouse et al., 2016), we recommend five key priorities to enhance the IPED intervention evidence
349 base which address the areas where the discrepancy between the IPED intervention field and what is
350 considered best practice within the broader field of implementation and intervention science is most
351 pronounced (see Box 1). This will support IPED researchers and practitioners to better respond to the
352 problems they identify through development and delivery of cost-effective interventions and,
353 ultimately, the identification of strategies to improve public health and the provision of support and
354 healthcare for people who use IPEDs.

Box 1: Five key priorities to improve the IPED intervention evidence base

1. Use available frameworks and guidance to support the development, implementation and evaluation of new interventions e.g., the Medical Research Council guidance (Craig et al., 2008)
2. Invest time in the early stages of development to develop a thorough understanding of the target population to ensure that interventions are based on a thorough assessment of the problem and context, and to prevent harmful effects.
3. Explore implementation factors in intervention development such as feasibility, reach, sustainability and acceptability, and identify possible unintended consequences. Consider pilot studies and process evaluations before full-scale implementation to understand these issues.
4. Evaluate existing and new interventions to understand whether they are effective, ineffective, or even harmful. Where feasible, use robust study designs and select appropriate outcomes to measure effectiveness against intervention goals.
5. Publish evaluation findings so that others can learn from and adapt effective interventions. Use relevant tools (e.g., TIDieR, Hoffmann et al., 2014) to support the reporting of interventions to increase transparency and knowledge transfer.

355

356 **Funding**

357 This research did not receive any specific grant from funding agencies in the public, commercial, or
358 not-for-profit sectors.

359

360 **REFERENCES**

- 361 ACMD. (2010). *Consideration of the Anabolic Steroids*. H. O. Advisory Council on the Misuse of Drugs.
362 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/119132/anabolic-steroids.pdf)
363 [data/file/119132/anabolic-steroids.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/119132/anabolic-steroids.pdf)
- 364
365 Backhouse, S. H., Whitaker, L., Patterson, L., Erickson, K., & McKenna, J. (2016). *Social psychology of*
366 *doping in sport: A mixed-studies narrative synthesis*. W. A.-D. Agency. [https://www.wada-](https://www.wada-ama.org/sites/default/files/resources/files/literature_review_update_-_final_2016.pdf)
367 [ama.org/sites/default/files/resources/files/literature_review_update - final 2016.pdf](https://www.wada-ama.org/sites/default/files/resources/files/literature_review_update_-_final_2016.pdf)
- 368
369 Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Lu, M. T., Hoffmann, U., & Pope H. G.
370 (2017). Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. *Circulation*,
371 135(21). <https://doi.org/https://doi.org/10.1161/CIRCULATIONAHA.116.026945>
- 372
373 Bartholomew, L. K., Parcel, G. S., Kok, G., & Gottlieb, N. H. (2006). *Planning health promotion*
374 *programs: An intervention mapping approach*. Jossey-Bass.
- 375
376 Bates, G., Begley, E., Tod, D., Jones, L., Leavey, C., & McVeigh, J. (2019). A systematic review
377 investigating the behaviour change strategies in interventions to prevent misuse of anabolic
378 steroids. *J Health Psychol*, 24(11), 1595-1612. <https://doi.org/10.1177/1359105317737607>
- 379
380 Bates, G., Jones, L., & McVeigh, J. (2014). *Update of NICE Guidance PH18 on 'Needle and syringe*
381 *programmes'*.
382 [http://allcatsrgrey.org.uk/wp/download/public_health/substance_misuse/Update-of-NICE-](http://allcatsrgrey.org.uk/wp/download/public_health/substance_misuse/Update-of-NICE-Guidance-PH18_Final-PIEDS-Review_170513.pdf)
383 [Guidance-PH18 Final-PIEDS-Review 170513.pdf](http://allcatsrgrey.org.uk/wp/download/public_health/substance_misuse/Update-of-NICE-Guidance-PH18_Final-PIEDS-Review_170513.pdf)
- 384
385 Bates, G., McVeigh, J., & Leavey, C. (2021). Looking beyond the provision of injecting equipment to
386 people who use anabolic androgenic steroids: Harm reduction and behaviour change goals
387 for UK policy. *Contemporary Drug Problems*.
- 388
389 Bates, G., Van Hout, M. C., Tay Wee Teck, J., & McVeigh, J. (2019). Treatments for people who use
390 anabolic androgenic steroids: a scoping review. *HARM REDUCTION JOURNAL*, 16(1).
391 <https://doi.org/https://doi.org/10.1186/s12954-019-0343-1>
- 392
393 Bjørnebekk, A., Westlye, L. T., Walhovd, K. B., Jørstad, M. L., Sundseth, Ø. Ø., & Fjell, A. M. (2019).
394 Cognitive performance and structural brain correlates in long-term anabolic-androgenic
395 steroid exposed and nonexposed weightlifters. *Neuropsychology*, 33(4), 547-559.
396 <https://doi.org/doi:10.1037/neu0000537>
- 397
398 Blank, C., Kopp, M., Niedermeier, M., Schnitzer, M., & Schobersberger, W. (2016). Predictors of
399 doping intentions, susceptibility, and behaviour of elite athletes: a meta-analytic review.
400 *SpringerPlus*, 5. <https://doi.org/DOI10.1186/s40064-016-3000-0>
- 401
402 Bonell, C., Jamal, F., Melendez-Torres, G. J., & Cummins, S. (2015). 'Dark logic': theorising the
403 harmful consequences of public health interventions. *J Epidemiol Community Health*, 69(1),
404 95-98. <https://doi.org/doi:10.1136/jech-2014-204671>

405
406 Brennan, R., Wells, J. S. G., & Van Hout, M. C. (2017). The injecting use of image and performance-
407 enhancing drugs (IPED) in the general population: a systematic review. *Health and Social*
408 *Care in the Community*, 25(5), 1459-1531. <https://doi.org/DOI: 10.1111/hsc.12326>

409
410 Brown, M. C., Sharp, L., Sniehotta, F. F., Skinner, R., & Araújo-Soares, V. (2020). The development of
411 health behaviour change interventions for childhood cancer survivors: the need for a
412 behavioural science approach. *Pediatric Blood & Cancer*, 67(9), e28500.
413 <https://doi.org/doi.org/10.1002/pbc.28500>

414
415 Campbell, N. C., Murray, E., Darbyshire, J., Emery, J., Farmer, A., Griffiths, F., Guthrie, B., Lester, H.,
416 Wilson, P., & Kinmonth, A. L. (2007). Designing and evaluating complex interventions to
417 improve health care. *Bmj*, 334(7591), 455-459.
418 <https://doi.org/10.1136/bmj.39108.379965.BE>

419
420 Childress, J. F., Faden, R. R., Gaare, R. D., Gostin, L. O., Kahn, J., Bonnie, R. J., Kass, N. E., Mastroianni,
421 A. C., Moreno, J. D., & Nieburg, P. (2002). Public health ethics: Mapping the terrain. *Journal*
422 *of Law, Medicine & Ethics*, 30, 170-178. [https://doi.org/https://doi.org/10.1111/j.1748-](https://doi.org/https://doi.org/10.1111/j.1748-720X.2002.tb00384.x)
423 [720X.2002.tb00384.x](https://doi.org/https://doi.org/10.1111/j.1748-720X.2002.tb00384.x)

424
425 Christiansen, A. V. (2020). *Gym Culture, Identity and Performance-Enhancing Drugs: Tracing a*
426 *Typology of Steroid Use*. Routledge.

427
428 Christiansen, A. V., Bloodworth, A., Ham, E., Cox, L., Gatterer, K., & Kjaer, R. (2019). *Forum for anti-*
429 *doping in recreational sport (FAIR) - Final report (Chapter 3)*. [www.ehfa-](http://www.ehfa-membership.com/sites/europeactive-euaffairs.eu/files/projects/FAIR/FAIR_Final_Report_web.pdf)
430 [memberships.com/sites/europeactive-](http://www.ehfa-membership.com/sites/europeactive-euaffairs.eu/files/projects/FAIR/FAIR_Final_Report_web.pdf)
431 [euaffairs.eu/files/projects/FAIR/FAIR_Final_Report_web.pdf](http://www.ehfa-membership.com/sites/europeactive-euaffairs.eu/files/projects/FAIR/FAIR_Final_Report_web.pdf)

432
433 Christiansen, A. V., Vinther, A. S. V., & Liokaftos, D. (2017). Outline of a typology of men's use of
434 anabolic androgenic steroids in fitness and strength training environments. *Drugs:*
435 *Education, Prevention and Policy*, 24(3), 295-305.
436 <https://doi.org/https://doi.org/10.1080/09687637.2016.1231173>

437
438 Christou, M. A., Christou, P. A., Markozannes, G., Tsatsoulis, A., Mastorakos, G., & Tigas, S. (2017).
439 Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and
440 Recreational Users: A Systematic Review and Meta-Analysis. *Sports Med*, 47(9), 1869-1883.
441 <https://doi.org/DOI: 10.1007/s40279-017-0709-z>

442
443 Council on Scientific Affairs. (1988). Drug abuse in athletes: anabolic steroids and human growth
444 hormone. *JAMA*, 259, 1703-1705. <https://doi.org/doi:10.1001/jama.1988.03720110065037>

445
446 Craig, P., Dieppe, P., MacIntyre, S., Michie, S., Nazareth, I., & Petticrew, M. (2008). *Developing and*
447 *evaluating complex interventions*. [https://mrc.ukri.org/documents/pdf/complex-](https://mrc.ukri.org/documents/pdf/complex-interventions-guidance/)
448 [interventions-guidance/](https://mrc.ukri.org/documents/pdf/complex-interventions-guidance/)

449

- 450 Dehnov, A., & Molero, Y. (2018). *Utvärdering av 100% ren hårdträning - en metod för att förebygga*
451 *dopning på gym.*
452 www.folkhalsomyndigheten.se/contentassets/15e7ae8c391e420ca89690c0aff1eaa/utvarde
453 [ring-100-ren-hardtraning.pdf](http://www.folkhalsomyndigheten.se/contentassets/15e7ae8c391e420ca89690c0aff1eaa/utvarde)
- 454
455 Des Jarlais, D. C., Lyles, C., Crepaz, N., & Trend, G. (2004). Improving the reporting quality of
456 nonrandomized evaluations of behavioral and public health interventions: the TREND
457 statement. *American journal of public health, 94*(3), 361-366.
458 <https://doi.org/10.2105/ajph.94.3.361>
- 459
460 Eccles, M. P., & Mittman, B. S. (2006). Welcome to implementation science.
461 <https://doi.org/doi.org/10.1186/1748-5908-1-1>
- 462
463 Elbe, A. M., & Brand, R. (2016). The effect of an ethical decision-making training on young athletes'
464 attitudes toward doping. *Ethics & Behavior, 26*(1), 32-44.
465 <https://doi.org/10.1080/10508422.2014.976864>
- 466
467 Elliot, D., Goldberg, L., Moe, E. L., DeFrancesco, C. A., Durham, M. B., & Hix-Small, H. (2004).
468 Preventing substance use and disordered eating - Initial outcomes of the ATHENA (Athletes
469 Targeting Healthy Exercise and Nutrition Alternatives) Program. *Archives of Pediatrics &*
470 *Adolescent Medicine, 158*(11), 1043-1049. <https://doi.org/10.1001/archpedi.158.11.1043>
- 471
472 Fraser, M. W., Richman, J. M., Galinsky, M. J., & Day, S. H. (2009). *Intervention research: Developing*
473 *social programs.* Oxford University Press.
- 474
475 Fulton, E. A., Brown, K. E., Kwah, K. L., & Wild, S. (2016, 2016). StopApp: using the behaviour change
476 wheel to develop an app to increase uptake and attendance at NHS Stop Smoking Services.
477 *Healthcare, 4*(2), 31. <https://doi.org/doi.org/10.3390/healthcare4020031>
- 478
479 Gitlin, L., & Czaja, S. (2015). *Behavioral intervention research: Designing, evaluating, and*
480 *implementing.* Springer Publishing Company.
- 481
482 Goldberg, L., Elliot, D., Clarke, G. N., MacKinnon, D. P., Moe, E., Zoref, L., Green, C., Wolf, S. L.,
483 Greffrath, E., Miller, D. J., & Lapin, A. (1996). Effects of a Multidimensional Anabolic Steroid
484 Prevention Intervention: The Adolescents Training and Learning to Avoid Steroids (ATLAS)
485 Program. *JAMA, 276*(19), 1555-1562.
486 <https://doi.org/doi:10.1001/jama.1996.03540190027025>
- 487
488 Goldberg, L., Elliot, D., MacKinnon, D. P., Moe, E., Kuehl, K. S., Nohre, L., & Lockwood, C. M. (2003).
489 Drug Testing Athletes to Prevent Substance Abuse: Background and Pilot Study Results of
490 the SATURN (Student Athlete Testing Using Random Notification) Study. *Journal of*
491 *Adolescent Health, 32*, 16-25. [https://doi.org/10.1016/s1054-139x\(02\)00444-5](https://doi.org/10.1016/s1054-139x(02)00444-5)
- 492
493 Goldberg, L., Elliot, D., MacKinnon, D. P., Moe, E., Kuehl, K. S., Yoon, M., Taylor, A., & Williams, J.
494 (2007). Outcomes of a Prospective Trial of Student-Athlete Drug Testing: The Student

495 Athlete Testing Using Random Notification (SATURN) Study. *Journal of Adolescent Health*,
496 41, 421-429. <https://doi.org/doi:10.1016/j.jadohealth.2007.08.001>

497
498 Goldberg, L., Elliot, D. L., Clarke, G. N., MacKinnon, D. P., Zoref, L., Moe, E., Green, C., & Wolf, S. L.
499 (1996, Jul). The Adolescents Training and Learning to Avoid Steroids (ATLAS) prevention
500 program - Background and results of a model intervention. *Archives of Pediatrics &*
501 *Adolescent Medicine*, 150(7), 713-721.
502 <https://doi.org/10.1001/archpedi.1996.02170320059010>

503
504 Gould, G. S., Bar-Zeev, Y., Bovill, M., Atkins, L., Gruppetta, M., Clarke, M. J., & Bonevski, B. (2017).
505 Designing an implementation intervention with the Behaviour Change Wheel for health
506 provider smoking cessation care for Australian Indigenous pregnant women. *Implementation*
507 *Science*, 12(1), 114. <https://doi.org/doi.org/10.1186/s13012-017-0645-1>

508
509 Hawe, P., Shiell, A., & Riley, T. (2009, Jun). Theorising interventions as events in systems. *American*
510 *Journal of Community Psychology*, 43(3-4), 267-276. [https://doi.org/10.1007/s10464-009-](https://doi.org/10.1007/s10464-009-9229-9)
511 [9229-9](https://doi.org/10.1007/s10464-009-9229-9)

512
513 Hawkins, J., Madden, K., Fletcher, A., Midgley, L., Grant, A., Cox, G., Moore, L., Campbell, R., Murphy,
514 S., & Bonell, C. (2017). Development of a framework for the co-production and prototyping
515 of public health interventions. *BMC Public Health*, 17.
516 <https://doi.org/doi.org/10.1186/s12889-017-4695-8>

517
518 HM Government. (2017). *2017 Drug Strategy*.
519 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/628148/Drug_strategy_2017.PDF)
520 [data/file/628148/Drug_strategy_2017.PDF](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/628148/Drug_strategy_2017.PDF)

521
522 Hoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D. G., Barbour,
523 V., Macdonald, H., Johnston, M., Lamb, S. E., Dixon-Woods, M., McCulloch, P., Wyatt, J. C.,
524 Chan, A.-W., & Michie, S. (2014). Better reporting of interventions: template for intervention
525 description and replication (TIDieR) checklist and guide. *BMJ : British Medical Journal*, 348.
526 <https://doi.org/10.1136/bmj.g1687>

527
528 Hope, V. D., Harris, R., McVeigh, J., Cullen, K. J., Smith, J., Parry, J. V., DeAngelis, D., & Ncube, F.
529 (2016). Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and
530 Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional
531 Prevalence Surveys, 1992–2013. *Journal of Acquired Immune Deficiency Syndromes*, 71(3),
532 331-337. <https://doi.org/https://dx.doi.org/10.1097%2FQAI.0000000000000835>

533
534 Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergård, A., Parry, J. V., &
535 Ncube, F. (2015). Injection site infections and injuries in men who inject image- and
536 performance-enhancing drugs: prevalence, risks factors, and healthcare seeking.
537 *Epidemiology & Infection*, 143(1), 132-140.
538 <https://doi.org/https://doi.org/10.1017/S0950268814000727>

539

- 540 Independent Expert Working Group. (2017). *Drug Misuse and Dependence: UK guidelines on clinical*
541 *management*.
542 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/673978/clinical_guidelines_2017.pdf)
543 [data/file/673978/clinical_guidelines_2017.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/673978/clinical_guidelines_2017.pdf)
- 544
545 Jalilian, F., Allahverdipour, H., Moeini, B., & Moghimbeigi, A. (2011). Effectiveness of Anabolic
546 Steroid Preventative Intervention among Gym Users: Applying Theory of Planned Behavior.
547 *Health Promotion Perspectives*, 1(1), 32-40. <https://doi.org/10.5681/hpp.2011.002>
- 548
549 Johannisson, M. R., Warnecke, M., Berget, J., Coumans, B., Wassink, H., Wigstad, C. R., Sjöblom, E.,
550 Rynkowski, M., & Petrou, M. (2012). *Strategy for Stopping Steroids*. A. D. Denmark.
551 https://www.antidoping.dk/media/1244/strategy_for_stopping_steroids.pdf
- 552
553 Kanayama, G., Brower, K., Wood, R., Hudson, J., & Pope, H. (2009). Anabolic-androgenic steroid
554 dependence: An emerging disorder. *Addiction*, 104(12), 1966-1978.
555 <https://doi.org/10.1111%2Fj.1360-0443.2009.02734.x>
- 556
557 Kimergard, A., & McVeigh, J. (2014, 2014/07/02/). Variability and dilemmas in harm reduction for
558 anabolic steroid users in the UK: a multi-area interview study [10.1186/1477-7517-11-19].
559 *HARM REDUCTION JOURNAL*, 11(ARTN 19). <https://doi.org/10.1186/1477-7517-11-19>
- 560
561 MacKinnon, D. P., Goldberg, L., Clarke, G. N., Elliott, D. L., Cheong, J., Lapin, A., Moe, E. L., & Krull, J.
562 L. (2001). Mediating mechanisms in a program to reduce intentions to use anabolic steroids
563 and improve exercise self-efficacy and dietary behavior. *Prevention Science*, 2(1), 15-28.
564 <https://doi.org/10.1023/A:1010082828000>
- 565
566 Marcello, R. J., Danish, S. J., & Stolberg, A. L. (1989). An Evaluation of Strategies Developed to
567 Prevent Substance Abuse Among Student-Athletes. *The Sport Psychologist*, 3, 196-211.
568 <https://doi.org/doi.org/10.1123/tsp.3.3.196>
- 569
570 McVeigh, J., & Begley, E. (2017). Anabolic steroids in the UK: an increasing issue for public health.
571 *Drugs: Education, Prevention and Policy*, 24(3), 278-285.
572 <https://doi.org/https://doi.org/10.1080/09687637.2016.1245713>
- 573
574 Michie, S., Atkins, L., & West, R. (2014). *The behaviour change wheel. A guide to designing*
575 *interventions*. Silverback Publishing.
- 576
577 Minary, L., Trompette, J., Kivits, J., Cambon, L., Tarquinio, C., & Alla, F. (2019). Which design to
578 evaluate complex interventions? Toward a methodological framework through a systematic
579 review. *BMC Medical Research Methodology*, 19(1), 1-9. [https://doi.org/10.1186/s12874-](https://doi.org/10.1186/s12874-019-0736-6)
580 [019-0736-6](https://doi.org/10.1186/s12874-019-0736-6)
- 581
582 Molero, Y., Gripenberg, J., & Bakshi, A.-S. (2016). Effectiveness and implementation of a community-
583 based prevention programme targeting anabolic androgenic steroid use in gyms: study
584 protocol of a quasi-experimental control group study. *BMC sports science, medicine and*
585 *rehabilitation*, 8(1), 36. <https://doi.org/10.1186/s13102-016-0062-9>

586
587 Moore, G., Audrey, S., Barker, M., Bond, L., Bonell, C., Hardeman, W., Moore, L., O’Cathain, A.,
588 Tinati, T., & Wight, D. (2014). *Process evaluation of complex interventions* (UK Medical
589 Research Council (MRC) guidance, Issue. [https://mrc.ukri.org/documents/pdf/mrc-phsrn-](https://mrc.ukri.org/documents/pdf/mrc-phsrn-process-evaluation-guidance-final/)
590 [process-evaluation-guidance-final/](https://mrc.ukri.org/documents/pdf/mrc-phsrn-process-evaluation-guidance-final/)

591
592 Moore, G. F., Evans, R. E., Hawkins, J., Littlecott, H., Melendez-Torres, G. J., Bonell, C., & Murphy, S.
593 (2019). From complex social interventions to interventions in complex social systems: future
594 directions and unresolved questions for intervention development and evaluation.
595 *Evaluation*, 25(1), 23-45. <https://doi.org/doi.org/10.1177/1356389018803219>

596
597 Morrison, C. (1994). Harm reduction with AS users: Experiences of running a well user service.
598 *RELAY*, 1(2), 16.

599
600 Morton, K. L., Atkin, A. J., Corder, K., Suhrcke, M., Turner, D., & Van Sluijs, E. M. F. (2017). Engaging
601 stakeholders and target groups in prioritising a public health intervention: the Creating
602 Active School Environments (CASE) online Delphi study. *BMJ open*, 7(1), e013340.
603 <https://doi.org/dx.doi.org/10.1136/bmjopen-2016-013340>

604
605 Movsisyan, A., Arnold, L., Evans, R., Hallingberg, B., Moore, G., O’Cathain, A., Pfadenhauer, L. M.,
606 Segrott, J., & Rehfuss, E. (2019). Adapting evidence-informed complex population health
607 interventions for new contexts: a systematic review of guidance. *Implementation Science*,
608 14(1), 105. <https://doi.org/doi.org/10.1186/s13012-019-0956-5>

609
610 NICE. (2014). *Needle and syringe programmes: NICE public health guidance 52*. National Institute for
611 Health and Care Excellence. Retrieved December 2018 from
612 <https://www.nice.org.uk/guidance/ph52>

613
614 Nilsen, P. (2015). Making sense of implementation theories, models and frameworks.
615 *Implementation Science*, 10(1), 53. <https://doi.org/doi.org/10.1186/s13012-015-0242-0>

616
617 Ntoumanis, N., Ng, J. Y. Y., Barkoukis, V., & Backhouse, S. H. (2014). Personal and psychosocial
618 predictors of doping in physical activity settings: A meta-analysis. *Sports Med*, 44, 1603-
619 1624. <https://doi.org/doi:10.1007/s40279-014-0240-4>

620
621 Nutter, J. (1993, March 24-28). Project Right Way: An anabolic steroid education program. Annual
622 Meeting of the American Alliance for Health, Physical Education, Recreation and Dance,
623 Washington DC.

624
625 O’Cathain, A., Croot, L., Sworn, K., Duncan, E., Rousseau, N., Turner, K., Yardley, L., & Hoddinott, P.
626 (2019). Taxonomy of approaches to developing interventions to improve health: a
627 systematic methods overview. *Pilot and feasibility studies*, 5(1), 41.
628 <https://doi.org/doi.org/10.1186/s40814-019-0425-6>

629

630 Oslo University Hospital. (2020). *Steroidprosjektet* Retrieved 09.01.2021 from [https://oslo-](https://oslo-universitetssykehus.no/fag-og-forskning/nasjonale-og-regionale-tjenester/tsb/nasjonal-kompetansetjeneste-tsb/vare-prosjekter/steroidprosjektet)
631 [universitetssykehus.no/fag-og-forskning/nasjonale-og-regionale-tjenester/tsb/nasjonal-](https://oslo-universitetssykehus.no/fag-og-forskning/nasjonale-og-regionale-tjenester/tsb/nasjonal-kompetansetjeneste-tsb/vare-prosjekter/steroidprosjektet)
632 [kompetansetjeneste-tsb/vare-prosjekter/steroidprosjektet](https://oslo-universitetssykehus.no/fag-og-forskning/nasjonale-og-regionale-tjenester/tsb/nasjonal-kompetansetjeneste-tsb/vare-prosjekter/steroidprosjektet)

633

634 Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014, Jun). Adverse Health
635 Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement.
636 *Endocrine Reviews*, 35(3), 341-375. <https://doi.org/10.1210/er.2013-1058>

637

638 Pope H. G., Kanayama, G., Athey, A., Ryan, E., Hudson, J. I., & Baggish, A. L. (2014). The lifetime
639 prevalence of anabolic-androgenic steroid use and dependence in Americans: Current best
640 estimates. *The American Journal of Addictions*, 23(4), 371-377.
641 <https://doi.org/https://doi.org/10.1111/j.1521-0391.2013.12118.x>

642

643 Rasmussen, J. J., Schou, M., Madsen, P. L., S Selmer, C., Johansen, M. L., Ulriksen, P. S., Dreyer, T.,
644 Kümler, T., Plesner, L. L., Faber, J., Gustafsson, F., & Kistorp, C. (2018). Cardiac systolic
645 dysfunction in past illicit users of anabolic androgenic steroids. *American Heart Journal*, 203,
646 49-56. <https://doi.org/doi:10.1016/j.ahj.2018.06.010>

647

648 Region Örebro County. (2020). *Dopningsmottagningen*. Retrieved 09.01.2021 from
649 <https://www.regionorebrolan.se/dopningsmottagningen>

650

651 Richards, D. A., & Hallberg, I. R. (2015). *Complex interventions in health: an overview of research*
652 *methods*. Routledge.

653

654 Sagoe, D., Andreassen, C. S., & Pallesen, S. (2014, Jul 2). The aetiology and trajectory of anabolic-
655 androgenic steroid use initiation: a systematic review and synthesis of qualitative research.
656 *Substance Abuse Treatment Prevention and Policy*, 9. [https://doi.org/10.1186/1747-597X-9-](https://doi.org/10.1186/1747-597X-9-27)
657 [27](https://doi.org/10.1186/1747-597X-9-27)

658

659 Sagoe, D., Holden, G., Rise, E. N. K., Torgersen, T., Paulsen, G., Krosshaug, T., Lauritzen, F., &
660 Pallesen, S. (2016). Doping prevention through anti-doping education and practical strength
661 training: The Hercules program. *Performance Enhancement & Health*, 5(1), 24-30.
662 <https://doi.org/https://doi.org/10.1016/j.peh.2016.01.001>

663

664 Sagoe, D., Molde, H., Andreassen, C. S., Torsheim, T., & Pallesen, S. (2014). The global epidemiology
665 of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. *Annals of*
666 *Epidemiology*, 24, 383-398. <https://doi.org/dx.doi.org/10.1016/j.annepidem.2014.01.009>

667

668 Schulz, K. F., Altman, D. G., Moher, D., & Consort, G. (2010). CONSORT 2010 statement: updated
669 guidelines for reporting parallel group randomised trials. *Trials*, 11(1), 32.
670 <https://doi.org/doi.org/10.1186/1741-7015-8-18>

671

672 Smit, D. L., & de Ronde, W. (2018). Outpatient clinic for users of anabolic androgenic steroids: an
673 overview. *Neth J Med*, 76(4), 167.

674

675 Thiblin, I., Garmo, H., Garle, M., Holmberg, L., Byberg, L., Michaëlsson, K., & Gedeberg, R. (2015).
676 Anabolic steroids and cardiovascular risk: A national population-based cohort study. *Drug*
677 *and Alcohol Dependence*, 152, 87-92.
678 <https://doi.org/https://doi.org/10.1016/j.drugalcdep.2015.04.013>

679
680 Tombor, I., Shahab, L., Brown, J., Crane, D., Michie, S., & West, R. (2016). Development of
681 SmokeFree Baby: a smoking cessation smartphone app for pregnant smokers. *Translational*
682 *behavioral medicine*, 6(4), 533-545. <https://doi.org/10.1007/s13142-016-0438-0>

683
684 van de Ven, K. (2016, 2016/06/01/). 'Blurred lines': Anti-doping, national policies, and the
685 performance and image enhancing drug (PIED) market in Belgium and The Netherlands.
686 *Performance Enhancement & Health*, 4(3), 94-102.
687 <https://doi.org/https://doi.org/10.1016/j.peh.2016.03.003>

688
689 Victora, C. G., Habicht, J.-P., & Bryce, J. (2004). Evidence-based public health: moving beyond
690 randomized trials. *American journal of public health*, 94(3), 400-405.
691 <https://doi.org/10.2105/ajph.94.3.400>

692
693 Wight, D., Wimbush, E., Jepson, R., & Doi, L. (2016). Six steps in quality intervention development
694 (6SQuID). *J Epidemiol Community Health*, 70(5), 520-525. [https://doi.org/doi:10.1136/jech-](https://doi.org/doi:10.1136/jech-2015-205952)
695 [2015-205952](https://doi.org/doi:10.1136/jech-2015-205952)

696
697 Zahnow, R., McVeigh, J., Bates, G., Hope, V. D., Kean, J., Campbell, J., & Smith, J. (2018). Identifying a
698 typology of men who use anabolic androgenic steroids (AAS). *International Journal of Drug*
699 *Policy*, 55, 105-112. <https://doi.org/https://doi.org/10.1016/j.drugpo.2018.02.022>

700
701